Henry J. Fuchs
2009
In 2009, Henry J. Fuchs earned a total compensation of $1.7M as Executive Vice President & Chief Medical Officer at BioMarin Pharmaceutical.
Compensation breakdown
| Non-Equity Incentive Plan | $180,400 |
|---|---|
| Option Awards | $923,200 |
| Salary | $339,038 |
| Stock Awards | $221,000 |
| Other | $54,934 |
| Total | $1,718,572 |
Fuchs received $923.2K in option awards, accounting for 54% of the total pay in 2009.
Fuchs also received $180.4K in non-equity incentive plan, $339K in salary, $221K in stock awards and $54.9K in other compensation.
Rankings
In 2009, Henry J. Fuchs' compensation ranked 2,789th out of 9,885 executives tracked by ExecPay. In other words, Fuchs earned more than 71.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,789 out of 9,885 | 72nd |
Division Manufacturing | 976 out of 3,690 | 74th |
Major group Chemicals And Allied Products | 191 out of 866 | 78th |
Industry group Drugs | 112 out of 638 | 82nd |
Industry Pharmaceutical Preparations | 89 out of 446 | 80th |
Source: SEC filing on March 23, 2012.
Fuchs' colleagues
We found four more compensation records of executives who worked with Henry J. Fuchs at BioMarin Pharmaceutical in 2009.
2009
Jean-Jacques Bienaim
BioMarin Pharmaceutical
Chief Executive Officer
2009
Stephen Aselage
BioMarin Pharmaceutical
Executive Vice President & Chief Business Officer
2009
Robert Baffi
BioMarin Pharmaceutical
Executive Vice President, Technical Operations
2009
Jeffrey Cooper
BioMarin Pharmaceutical
Chief Financial Officer
News
BioMarin Pharmaceutical CEO Jean-Jacques Bienaim's 2021 pay rises 1% to $18M
April 12, 2022
BioMarin Pharmaceutical CEO Jean-Jacques Bienaim's 2020 pay slips 2% to $18M
April 13, 2021
BioMarin Pharmaceutical CEO Jean-Jacques Bienaim's 2019 pay rises 18% to $18M
April 14, 2020
BioMarin Pharmaceutical CEO Jean-Jacques Bienaim's 2018 pay slips 2% to $16M
April 23, 2019